ZTS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 28.42% compared to Zoetis's net margin of 21.68%. Zoetis's return on equity of 51.03% beat Eli Lilly and's return on equity of 78.25%.

Zoetis has a consensus price target of $195.37, signalling upside risk potential of 18.85%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 20.31%. Given that Eli Lilly and has higher upside potential than Zoetis, analysts believe Eli Lilly and is more attractive than Zoetis.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.913% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.13%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Zoetis pays 31.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Zoetis's net income of $631M is lower than Eli Lilly and's net income of $2.8B. Notably, Zoetis's price-to-earnings ratio is 29.51x while Eli Lilly and's PE ratio is 64.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 14.58x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 28.42% compared to Zoetis's net margin of -907.48%. Zoetis's return on equity of 51.03% beat Moderna's return on equity of -29.23%.

Zoetis has a consensus price target of $195.37, signalling upside risk potential of 18.85%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 86.27%. Given that Moderna has higher upside potential than Zoetis, analysts believe Moderna is more attractive than Zoetis.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.913% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.13%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are larger than Moderna quarterly revenues of $107M. Zoetis's net income of $631M is higher than Moderna's net income of -$971M. Notably, Zoetis's price-to-earnings ratio is 29.51x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 3.17x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 28.42% compared to Zoetis's net margin of 21.63%. Zoetis's return on equity of 51.03% beat Pfizer's return on equity of 8.72%.

Zoetis has a consensus price target of $195.37, signalling upside risk potential of 18.85%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 21.83%. Given that Pfizer has higher upside potential than Zoetis, analysts believe Pfizer is more attractive than Zoetis.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.913% less volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.13%. Pfizer offers a yield of 7.08% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.2B, which are smaller than Pfizer quarterly revenues of $13.7B. Zoetis's net income of $631M is lower than Pfizer's net income of $3B. Notably, Zoetis's price-to-earnings ratio is 29.51x while Pfizer's PE ratio is 17.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 2.19x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 28.42% compared to Zoetis's net margin of -7.89%. Zoetis's return on equity of 51.03% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Zoetis has a consensus price target of $195.37, signalling upside risk potential of 18.85%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 20.65%. Given that Supernus Pharmaceuticals has higher upside potential than Zoetis, analysts believe Supernus Pharmaceuticals is more attractive than Zoetis.

Zoetis has a beta of 0.941, which suggesting that the stock is 5.913% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.985%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.13%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Zoetis's net income of $631M is higher than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Zoetis's price-to-earnings ratio is 29.51x while Supernus Pharmaceuticals's PE ratio is 29.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.00x versus 2.71x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.